Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt(Dana-Farber Cancer Institute), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), David I. Quinn(USC Norris Comprehensive Cancer Center), David J. Vaughn(University of Pennsylvania), Winald R. Gerritsen(Amsterdam UMC Location Vrije Universiteit Amsterdam), Howard Gurney(Radboud University Nijmegen), Ronald de Wit(Erasmus MC Cancer Institute), Daniel P. Petrylak(Yale University), Toni K. Choueiri(Harvard University), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Jae‐Lyun Lee(Ulsan College), Rodolfo F. Perini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yabing Mai(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center), Yves Fradet(Centre hospitalier universitaire de Québec), Andrea Necchi(Vita-Salute San Raffaele University), Miguel Ángel Climent(Radboud University Nijmegen), Cora N. Sternberg(Cornell University), Stéphane Culine(Radboud University Nijmegen), Christian Poehlein(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 3,384
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k